BioSpace News Archive

Astex Pharmaceuticals and The Medicines Discovery Institute, Cardiff University announced that they have entered into a multi-year, multimillion pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases.

LegoChem Biosciences Inc. announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology company in Switzerland, to develop and commercialize a novel antibody-drug conjugate therapy using a monoclonal antibody developed by Elthera.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced topline results from its pivotal Phase 3 PRESERVE 1 trial showing that the trial achieved its co-primary endpoints related to severe neutropenia with statistical significance; however, early anti-tumor efficacy data, including overall response rate (ORR) and preliminary measures of survival, favored the placebo arm.

Opthea Limited (NASDAQ:OPT; ASX:OPT) announced today that the Phase 2b study results of OPT-302, the Company’s anti-VEGF-C/-D “trap” agent administered in combination with Lucentis® (ranibizumab) for the treatment of wet age-related macular degeneration (AMD), have been published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

The new holding company name is The Cigna Group. The Cigna Group is a global health company committed to improving health and vitality.

Eli Lilly and Company (NYSE: LLY) will supply its active pharmaceutical ingredient (API) for human insulin at a reduced price to International Agencies (Bangladesh) Ltd. (IABL) in an effort to increase patient access and improve affordability for high-quality insulin for nearly one million people living with diabetes in Bangladesh by 2030.

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, and Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced Insulet has acquired assets related to Bigfoot’s pump-based automated insulin delivery (AID) technologies.

Rockwell Medical, Inc. announced that the Company signed a three-year product purchase agreement with Concerto Renal Services, the largest provider of dialysis in skilled nursing facilities in the United States.

Cycle Pharmaceuticals Ltd (Cycle) has today announced the launch of TASCENSO ODT, its first product to treat MS patients in the US.

Henry Schein, Inc. announced that its Board of Directors has authorized the repurchase of up to $400 million of shares of the Company’s common stock.